Presence of retinopathy and incident kidney and cardiovascular events in type 2 diabetes with normoalbuminuria - A post-hoc analysis of the PRIORITY randomized clinical trial

Viktor Rotbain Curovic; N Tofte; M Lindhardt; K Adamova; Stephan J.L. Bakker; J Beige; JWJ Beulens; AL Birkenfeld; G Currie; C Delles; I Dimos; L Francová; M Frimodt-Moller; P Girman; R Göke; TW Hansen; T Havrdova; A Kooy; Gozewijn D. Laverman; H Mischak; G Navis; G Nijpels; M Noutsou; A Ortiz; A Parvanova; F Persson; JR Petrie; PL Ruggenenti; F Rutters; I Rychlík; J Siwy; G Spasovski; M Speeckaert; M Trillini; P Zürbig; H von der Leyen; P Rossing; PRIORITY Study Grp

doi:10.1016/j.jdiacomp.2023.108433

Presence of retinopathy and incident kidney and cardiovascular events in type 2 diabetes with normoalbuminuria - A post-hoc analysis of the PRIORITY randomized clinical trial

Viktor Rotbain Curovic^*, N Tofte, M Lindhardt, K Adamova, Stephan J.L. Bakker, J Beige, JWJ Beulens, AL Birkenfeld, G Currie, C Delles, I Dimos, L Francová, M Frimodt-Moller, P Girman, R Göke, TW Hansen, T Havrdova, A Kooy, Gozewijn D. Laverman, H MischakG Navis, G Nijpels, M Noutsou, A Ortiz, A Parvanova, F Persson, JR Petrie, PL Ruggenenti, F Rutters, I Rychlík, J Siwy, G Spasovski, M Speeckaert, M Trillini, P Zürbig, H von der Leyen, P Rossing, PRIORITY Study Grp

^*Corresponding author for this work

Research output: Contribution to journal › Article › Academic › peer-review

2 Citations (Scopus)

Abstract

Aims: Baseline diabetic retinopathy (DR) and risk of development of microalbuminuria, kidney function decline, and cardiovascular events (CVEs) in type 2 diabetes. Methods: Post-hoc analysis of the PRIORITY study including 1758 persons with type 2 diabetes and normoalbuminuria followed for a median of 2.5 (IQR: 2.0–3.0) years. DR diagnosis included non-proliferative and proliferative abnormalities, macular oedema, or prior laser treatment. Cox models were fitted to investigate baseline DR presence with development of persistent microalbuminuria (urinary albumin-creatinine ratio > 30 mg/g); chronic kidney disease (CKD) G3 (eGFR <60 ml/min/1.73m ²); and CVE. Models were adjusted for relevant risk factors. Results: At baseline, 304 (17.3 %) had DR. Compared to persons without DR, they were older (mean ± SD: 62.7 ± 7.7 vs 61.4 ± 8.3 years, p = 0.019), had longer diabetes duration (17.9 ± 8.4 vs. 10.6 ± 7.0 years, p < 0.001), and higher HbA _1c (62 ± 13 vs. 56 ± 12 mmol/mol, p < 0.001). The adjusted hazard ratios of DR at baseline for development of microalbuminuria (n = 197), CKD (n = 166), and CVE (n = 64) were: 1.50 (95%CI: 1.07, 2.11), 0.87 (95%CI: 0.56, 1.34), and 2.61 (95%CI: 1.44, 4.72), compared to without DR. Conclusions: Presence of DR in normoalbuminuric type 2 diabetes was associated with an increased risk of developing microalbuminuria and CVE, but not with kidney function decline.

Original language	English
Article number	108433
Number of pages	7
Journal	Journal of diabetes and its complications
Volume	37
Issue number	4
Early online date	18 Feb 2023
DOIs	https://doi.org/10.1016/j.jdiacomp.2023.108433
Publication status	Published - Apr 2023
Externally published	Yes

Keywords

Albuminuria
Cardiovascular disease
Chronic kidney disease
Diabetic retinopathy
Risk stratification
Type 2 diabetes
n/a OA procedure

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.jdiacomp.2023.108433

Cite this

Curovic, V. R., Tofte, N., Lindhardt, M., Adamova, K., Bakker, S. J. L., Beige, J., Beulens, JWJ., Birkenfeld, AL., Currie, G., Delles, C., Dimos, I., Francová, L., Frimodt-Moller, M., Girman, P., Göke, R., Hansen, TW., Havrdova, T., Kooy, A., Laverman, G. D., ... PRIORITY Study Grp (2023). Presence of retinopathy and incident kidney and cardiovascular events in type 2 diabetes with normoalbuminuria - A post-hoc analysis of the PRIORITY randomized clinical trial. Journal of diabetes and its complications, 37(4), Article 108433. https://doi.org/10.1016/j.jdiacomp.2023.108433

@article{c34f7f114ae645f0b037aba9b4466846,

title = "Presence of retinopathy and incident kidney and cardiovascular events in type 2 diabetes with normoalbuminuria - A post-hoc analysis of the PRIORITY randomized clinical trial",

abstract = "Aims: Baseline diabetic retinopathy (DR) and risk of development of microalbuminuria, kidney function decline, and cardiovascular events (CVEs) in type 2 diabetes. Methods: Post-hoc analysis of the PRIORITY study including 1758 persons with type 2 diabetes and normoalbuminuria followed for a median of 2.5 (IQR: 2.0–3.0) years. DR diagnosis included non-proliferative and proliferative abnormalities, macular oedema, or prior laser treatment. Cox models were fitted to investigate baseline DR presence with development of persistent microalbuminuria (urinary albumin-creatinine ratio > 30 mg/g); chronic kidney disease (CKD) G3 (eGFR <60 ml/min/1.73m 2); and CVE. Models were adjusted for relevant risk factors. Results: At baseline, 304 (17.3 %) had DR. Compared to persons without DR, they were older (mean ± SD: 62.7 ± 7.7 vs 61.4 ± 8.3 years, p = 0.019), had longer diabetes duration (17.9 ± 8.4 vs. 10.6 ± 7.0 years, p < 0.001), and higher HbA 1c (62 ± 13 vs. 56 ± 12 mmol/mol, p < 0.001). The adjusted hazard ratios of DR at baseline for development of microalbuminuria (n = 197), CKD (n = 166), and CVE (n = 64) were: 1.50 (95%CI: 1.07, 2.11), 0.87 (95%CI: 0.56, 1.34), and 2.61 (95%CI: 1.44, 4.72), compared to without DR. Conclusions: Presence of DR in normoalbuminuric type 2 diabetes was associated with an increased risk of developing microalbuminuria and CVE, but not with kidney function decline.",

keywords = "Albuminuria, Cardiovascular disease, Chronic kidney disease, Diabetic retinopathy, Risk stratification, Type 2 diabetes, n/a OA procedure",

author = "Curovic, {Viktor Rotbain} and N Tofte and M Lindhardt and K Adamova and Bakker, {Stephan J.L.} and J Beige and JWJ Beulens and AL Birkenfeld and G Currie and C Delles and I Dimos and L Francov{\'a} and M Frimodt-Moller and P Girman and R G{\"o}ke and TW Hansen and T Havrdova and A Kooy and Laverman, {Gozewijn D.} and H Mischak and G Navis and G Nijpels and M Noutsou and A Ortiz and A Parvanova and F Persson and JR Petrie and PL Ruggenenti and F Rutters and I Rychl{\'i}k and J Siwy and G Spasovski and M Speeckaert and M Trillini and P Z{\"u}rbig and {von der Leyen}, H and P Rossing and {PRIORITY Study Grp}",

year = "2023",

month = apr,

doi = "10.1016/j.jdiacomp.2023.108433",

language = "English",

volume = "37",

journal = "Journal of diabetes and its complications",

issn = "1056-8727",

publisher = "Elsevier Inc.",

number = "4",

}

Curovic, VR, Tofte, N, Lindhardt, M, Adamova, K, Bakker, SJL, Beige, J, Beulens, JWJ, Birkenfeld, AL, Currie, G, Delles, C, Dimos, I, Francová, L, Frimodt-Moller, M, Girman, P, Göke, R, Hansen, TW, Havrdova, T, Kooy, A, Laverman, GD, Mischak, H, Navis, G, Nijpels, G, Noutsou, M, Ortiz, A, Parvanova, A, Persson, F, Petrie, JR, Ruggenenti, PL, Rutters, F, Rychlík, I, Siwy, J, Spasovski, G, Speeckaert, M, Trillini, M, Zürbig, P, von der Leyen, H, Rossing, P & PRIORITY Study Grp 2023, 'Presence of retinopathy and incident kidney and cardiovascular events in type 2 diabetes with normoalbuminuria - A post-hoc analysis of the PRIORITY randomized clinical trial', Journal of diabetes and its complications, vol. 37, no. 4, 108433. https://doi.org/10.1016/j.jdiacomp.2023.108433

Presence of retinopathy and incident kidney and cardiovascular events in type 2 diabetes with normoalbuminuria - A post-hoc analysis of the PRIORITY randomized clinical trial. / Curovic, Viktor Rotbain; Tofte, N; Lindhardt, M et al.
In: Journal of diabetes and its complications, Vol. 37, No. 4, 108433, 04.2023.

Research output: Contribution to journal › Article › Academic › peer-review

TY - JOUR

T1 - Presence of retinopathy and incident kidney and cardiovascular events in type 2 diabetes with normoalbuminuria - A post-hoc analysis of the PRIORITY randomized clinical trial

AU - Curovic, Viktor Rotbain

AU - Tofte, N

AU - Lindhardt, M

AU - Adamova, K

AU - Bakker, Stephan J.L.

AU - Beige, J

AU - Beulens, JWJ

AU - Birkenfeld, AL

AU - Currie, G

AU - Delles, C

AU - Dimos, I

AU - Francová, L

AU - Frimodt-Moller, M

AU - Girman, P

AU - Göke, R

AU - Hansen, TW

AU - Havrdova, T

AU - Kooy, A

AU - Laverman, Gozewijn D.

AU - Mischak, H

AU - Navis, G

AU - Nijpels, G

AU - Noutsou, M

AU - Ortiz, A

AU - Parvanova, A

AU - Persson, F

AU - Petrie, JR

AU - Ruggenenti, PL

AU - Rutters, F

AU - Rychlík, I

AU - Siwy, J

AU - Spasovski, G

AU - Speeckaert, M

AU - Trillini, M

AU - Zürbig, P

AU - von der Leyen, H

AU - Rossing, P

AU - PRIORITY Study Grp

PY - 2023/4

Y1 - 2023/4

N2 - Aims: Baseline diabetic retinopathy (DR) and risk of development of microalbuminuria, kidney function decline, and cardiovascular events (CVEs) in type 2 diabetes. Methods: Post-hoc analysis of the PRIORITY study including 1758 persons with type 2 diabetes and normoalbuminuria followed for a median of 2.5 (IQR: 2.0–3.0) years. DR diagnosis included non-proliferative and proliferative abnormalities, macular oedema, or prior laser treatment. Cox models were fitted to investigate baseline DR presence with development of persistent microalbuminuria (urinary albumin-creatinine ratio > 30 mg/g); chronic kidney disease (CKD) G3 (eGFR <60 ml/min/1.73m 2); and CVE. Models were adjusted for relevant risk factors. Results: At baseline, 304 (17.3 %) had DR. Compared to persons without DR, they were older (mean ± SD: 62.7 ± 7.7 vs 61.4 ± 8.3 years, p = 0.019), had longer diabetes duration (17.9 ± 8.4 vs. 10.6 ± 7.0 years, p < 0.001), and higher HbA 1c (62 ± 13 vs. 56 ± 12 mmol/mol, p < 0.001). The adjusted hazard ratios of DR at baseline for development of microalbuminuria (n = 197), CKD (n = 166), and CVE (n = 64) were: 1.50 (95%CI: 1.07, 2.11), 0.87 (95%CI: 0.56, 1.34), and 2.61 (95%CI: 1.44, 4.72), compared to without DR. Conclusions: Presence of DR in normoalbuminuric type 2 diabetes was associated with an increased risk of developing microalbuminuria and CVE, but not with kidney function decline.

AB - Aims: Baseline diabetic retinopathy (DR) and risk of development of microalbuminuria, kidney function decline, and cardiovascular events (CVEs) in type 2 diabetes. Methods: Post-hoc analysis of the PRIORITY study including 1758 persons with type 2 diabetes and normoalbuminuria followed for a median of 2.5 (IQR: 2.0–3.0) years. DR diagnosis included non-proliferative and proliferative abnormalities, macular oedema, or prior laser treatment. Cox models were fitted to investigate baseline DR presence with development of persistent microalbuminuria (urinary albumin-creatinine ratio > 30 mg/g); chronic kidney disease (CKD) G3 (eGFR <60 ml/min/1.73m 2); and CVE. Models were adjusted for relevant risk factors. Results: At baseline, 304 (17.3 %) had DR. Compared to persons without DR, they were older (mean ± SD: 62.7 ± 7.7 vs 61.4 ± 8.3 years, p = 0.019), had longer diabetes duration (17.9 ± 8.4 vs. 10.6 ± 7.0 years, p < 0.001), and higher HbA 1c (62 ± 13 vs. 56 ± 12 mmol/mol, p < 0.001). The adjusted hazard ratios of DR at baseline for development of microalbuminuria (n = 197), CKD (n = 166), and CVE (n = 64) were: 1.50 (95%CI: 1.07, 2.11), 0.87 (95%CI: 0.56, 1.34), and 2.61 (95%CI: 1.44, 4.72), compared to without DR. Conclusions: Presence of DR in normoalbuminuric type 2 diabetes was associated with an increased risk of developing microalbuminuria and CVE, but not with kidney function decline.

KW - Albuminuria

KW - Cardiovascular disease

KW - Chronic kidney disease

KW - Diabetic retinopathy

KW - Risk stratification

KW - Type 2 diabetes

KW - n/a OA procedure

U2 - 10.1016/j.jdiacomp.2023.108433

DO - 10.1016/j.jdiacomp.2023.108433

M3 - Article

C2 - 36841085

SN - 1056-8727

VL - 37

JO - Journal of diabetes and its complications

JF - Journal of diabetes and its complications

IS - 4

M1 - 108433

ER -

Presence of retinopathy and incident kidney and cardiovascular events in type 2 diabetes with normoalbuminuria - A post-hoc analysis of the PRIORITY randomized clinical trial

Abstract

Keywords

UN SDGs

Access to Document

Fingerprint

Cite this